Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
After the start of the vaccination against the coronavirus in Argentina, with the Russian vaccine Sputnik V, this Tuesday, another good news arrived in the country concerning the fight against the pandemic. It is because the National Administration of Medicines, Food and Medical Technology (ANMAT), has validated the vaccine AZD1222 from Oxford / AstraZeneca in Argentina, under emergency use, given that it presents an acceptable benefit-risk ratio “.
This vaccine has been approved by the one year term from the date of this provision, under the condition of prescription sale and serves precisely for the active vaccination of people over 18 with two doses administered 4 to 12 weeks apart, as initially recommended by the UK regulatory agency (MHRA).
This institution has been authorized as emergency power ensuring that in phase III clinical trials, this regimen has been shown to be safe and effective in preventing symptomatic COVID-19, without severe cases or hospitalization more than 14 days after the second dose.
The national government has reached an agreement to acquire in March, 22.4 million doses, who will cover 11 million Argentines upon arrival. The fundamental contribution of this vaccine will be produced in Argentina – by the laboratory mAbxience, member of the pharmaceutical group Insud Pharma– and regional packaging and distribution will be from Mexico.
It is a vaccine that is presented as suitable for emerging countries while having better access and better price, better dose delivery and better transport as it can be stored for long periods of time at normal refrigeration temperatures.
AstraZeneca has entered into several agreements in India, China, Europe, Russia to produce 3 billion doses of vaccines over the next year.
The laboratory AstraZeneca has determined in the second quarter of the year what will be its production and distribution strategy of its vaccine in Latin America, with the exception of Brazil. AND in August, he announced that Argentina would be in charge of the production the active ingredient and the packaging and distribution will be in Mexico, it must supply the other Latin American countries.
.
[ad_2]
Source link
